Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43839   clinical trials with a EudraCT protocol, of which   7280   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2018-004405-64
    Sponsor's Protocol Code Number:MT-2-03
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-12-19
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2018-004405-64
    A.3Full title of the trial
    A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study comparing the effect of MIN-102 and an inactive substance to learn more about the effects of the MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia, in which neither investigators nor subjects know what treatment the subject is receiving.
    Studie zum Vergleich der Auswirkungen von MIN-102 und einer inaktiven Substanz, um mehr über die Auswirkungen des MIN-102 auf biochemische, bildgebende, neurophysiologische und klinische Marker bei Patienten mit Friedreich-Ataxie zu erfahren, in denen weder die Ermittler noch die Versuchspersonen wissen, welche Substanz der Patient erhält.
    A.4.1Sponsor's protocol code numberMT-2-03
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMinoryx Therapeutics BE, SA
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMinoryx Therapeutics S.L.
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMinoryx Therapeutics S.L.
    B.5.2Functional name of contact pointSílvia Pascual
    B.5.3 Address:
    B.5.3.1Street AddressAv. Ernest Lluch 32, TCM3
    B.5.3.2Town/ cityMataró (Barcelona)
    B.5.3.3Post code08302
    B.5.4Telephone number0034935441466
    B.5.5Fax number0034930160119
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride
    D.3.2Product code MIN-102
    D.3.4Pharmaceutical form Oral suspension
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INN5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride
    D.3.9.1CAS number 146062-46-6
    D.3.9.2Current sponsor codeMIN-102
    D.3.9.3Other descriptive nameHydroxypioglitazone hydrochloride
    D.3.9.4EV Substance CodeSUB16466MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral suspension
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Friedreich’s Ataxia
    E.1.1.1Medical condition in easily understood language
    Friedreich’s Ataxia
    E.1.1.2Therapeutic area Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10017374
    E.1.2Term Friedreich's ataxia
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    to evaluate the effect of 48 weeks of treatment with MIN-102 compared to placebo on cervical spinal cord area as assessed by morphometric MRI measurements.
    Das Primärziel der Studie besteht darin, die Wirkung der 48-wöchigen Behandlung mit MIN-102 im Vergleich zu Placebo auf den Bereich des Rückenmarks der Halswirbelsäule anhand von morphometrischen MRT-Messungen zu beurteilen.
    E.2.2Secondary objectives of the trial
    To evaluate the effect of 48 wks of treatment with MIN-102 compared to placebo as follow:
    -Change from baseline in the total score of SARA
    -Cervical spinal cord mean, axial and radial diffusivity as assessed by MRI DTI
    -Cervical spinal cord tNAA/mIns ratio as assessed by MRS
    -MRI quantitative susceptibility mapping for iron concentration
    -Dentate nuclei volume
    -Brain fiber density, fiber cross-section and fiber density and cross-section as assessed by fixel-based analyses
    -Cerebellar Composite Functional Scale, composed of 2 functional tests
    -Fatigue Severity Scale
    -Activities of daily living (FARS)
    -Clinician and patient global impressions of improvement
    -Change in the pre-treatment versus post-treatment slope of the SARA
    -Neurophysiological parameters as assessed by motor evoked potentials (MEP). Optional assessment
    -Various biochemical parameters in plasma, and CSF. Optional assessment.
    -Safety and tolerability of MIN-102
    Sekundärziele: 48-wöchige Behandlung mit MIN102 im Vergleich zu Placebo
    • Veränderung SARA-Gesamtwert zu Baseline
    • Mittelwert, axiale und radiale Diffusionsfähigkeit des Rückenmarks der Halswirbelsäule anhand MRT DTI
    • tNAA/mIns-Verhältnis des Rückenmarks der Halswirbelsäule anhand MRS
    • MRT quantitative Suszeptibilitätskartierung der Eisenkonzentration
    • Volumen der Zahnkerne
    • Gehirnfaserdichte, Faserquerschnitt und Faserdichte und -querschnitt anhand der Fixel-basierte Analysen
    • Cerebellar Composite Functional Scale
    • Lebensqualität (EQ-5D-5L)
    • Fatigue Severity Scale (FSS)
    • Aktivitäten im Alltag (Subskala der Müdigkeit)
    • Allgemeiner Eindruck des Arztes und des Patienten bezüglich Verbesserung
    • Veränderung des SARA-Ratings im Vergleich vor und nach der Behandlung
    • Neurophysiologische Parameter anhand der Bewertung durch motorisch evozierte Potenziale
    • Verschiedene biochemische Parameter in Plasma und CSF
    • Sicherheit und Verträglichkeit von MIN-102
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Signed Informed Consent by the subject or parent/legal guardian, and/or consent or assent for minors as required by national laws.
    2. Male and female subjects aged ≥12 and ≤60 years, inclusive, with Friedreich’s Ataxia confirmed by genetic testing.
    3. Total score on SARA of <25.
    4. Score on SARA item 1 (gait) ≥2 and ≤6.
    5. Male with a potentially fertile partner must be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation (acceptable methods are: use of a condom with spermicide or use of oral, implantable or injectable contraceptives, or intrauterine devices, or a diaphragm with spermicide or diaphragm with condom) or have had a vasectomy.
    6. Female with childbearing potential must be willing to use highly effective contraceptive methods during screening, during the period of drug administration and for 30 days after stopping study drug administration. Highly effective contraception methods include the following:
    ▪ Total abstinence (defined as refraining from heterosexual intercourse during the entire period outlined above).
    ▪ Male or female sterilization. (bilateral tubal occlusion or vasectomized partner)
    ▪ Use of at least one of the following:
    a. Use of oral, injectable, transdermal, intravaginal, or implantable hormonal methods of contraception
    ▪ combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: Oral, intravaginal or transdermal.
    ▪ progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable
    b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    7. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days before first administration of study drug.
    1.Unterzeichnung der Einwilligungserklärung durch den Patienten oder Elternteil/Erziehungsberechtigten und/oder Einwilligung oder Zustimmung bei Minderjährigen
    2. Männliche und weibliche Patientenim Alter von einschließlich ≥ 12 und ≤ 60 Jahren, mit Friedreich-Ataxie, die durch Gentests bestätigt wurde.
    3. SARA-Gesamtwert von <25.
    4. Wert des SARA-Items 1 (Gang) ≥2 und ≤6.
    5. Männer mit einer potenziell gebärfähigen Partnerin haben sich bereits einer Vasektomie unterzogen oder müssen bereit sein, für die Dauer der Studie und bis 3 Monate nach Absetzen des Studienmedikaments eine zulässige Verhütungsmethode anzuwenden (zulässige Methoden sind: die Anwendung eines Kondoms mit Spermizid oder die Anwendung von oralen, implantierbaren oder injizierbaren Verhütungsmitteln oder Intrauterinpessaren oder eines Diaphragmas mit Spermizid oder eines Diaphragmas mit Kondom).
    6. Gebärfähige Frauen müssen bereit sein, während sowie bis 30 Tage nach dem Ende der Verabreichung des Studienmedikaments höchst zuverlässige Empfängnisverhütungsmethoden anzuwenden. Zu den höchst zuverlässigen Empfängnisverhütungsmethoden gehören die folgenden:
    -Vollständige Enthaltsamkeit (definiert als Nichtausüben heterosexuellen Geschlechtsverkehrs während des gesamten oben genannten Zeitraums).
    -Sterilisierung des Mannes oder der Frau.
    -beidseitiger Tubenverschluss
    -Vasektomie beim Partner
    -Anwendung von zumindest einem der folgenden Verhütungsmittel:
    a. Anwendung oraler, injizierter, transdermaler, intravaginaler oder implantierbarer Hormonverhütungsmethoden
    -kombinierte (östrogen- und gestagenhaltige) hormonelle Verhütung als Ovulationshemmer: Oral, intravaginal oder transdermal.
    -hormonelle, nur Gestagen enthaltende, ovulationshemmende Verhütungsmittel: oral, injizierbar oder implantierbar
    b.Einsetzung eines Intrauterinpessars (IUP) oder intrauterinen Systems (IUS)
    7. Gebärfähige Patientinnen müssen innerhalb von 7 Tagen vor der ersten Verabreichung des Studienmedikaments ein negatives Serum-Schwangerschaftstestergebnis vorweisen.
    E.4Principal exclusion criteria
    1. Age of onset of disease ≥25 years
    2. Left ventricular ejection fraction (LVEF) <55%, on echocardiogram.
    3. Subjects with a history of heart failure, ventricular arrhythmia, supraventricular tachycardia, or having a QTcF time of >480 msec in 3 consecutive ECG recordings taken at least 5 minutes apart.
    4. Known intolerance to pioglitazone or other thiazolidinediones.
    5. Subjects who are taking or have taken pioglitazone, or other thiazolidinediones, within the past 6 months prior to Screening.
    6. Currently participating in or having participated in another interventional clinical study within 2 months prior to Screening.
    7. Requiring other prohibited concomitant medication (see Table 4). Note: use of idebenone, coenzyme Q10, antioxidants, riboflavin, thiamine, vitamins C and E is permitted provided the dose has been constant for ≥3 months before Screening and is kept constant during the entire study.
    8. Previous or current history of vesical polyps, bladder cell hyperplasia, or bladder cancer.
    9. Previous or current history of other cancer, unless surgically resected and without evidence of recurrence for a minimum of 5 years.
    10. Subjects with clinically significant anemia (i.e. hemoglobin below 110 g/L).
    11. Glycated hemoglobin (HbA1c) levels >6.4% and fasting blood glucose levels ≤ 0.9 times the lower limit of normal and ≥ 1.1 times the upper limit of normal.
    12. NT-proB-type natriuretic peptide level (NT pro BNP) >125 pg/mL
    13. Abnormal liver enzyme tests for aspartate aminotransferase or alanine aminotransferase of >2 times the upper limit of normal or total bilirubin >1.5 times the upper limit of normal (unless
    due to Gilbert’s syndrome).
    14. A positive result on laboratory tests for hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus antibody at screening.
    15. Moderate or severe hepatic impairment (groups B and C according to the revised Child-Pugh classification; (Pugh, Murray-Lyon et al. 1973).
    16. Chronic kidney disease (CKD) stages 3a or higher (according to CKD staging by Renal Association with an estimated glomerular filtration rate of <60 ml/min/1.73m2).
    17. Contraindications for MRS/MRI procedure such as subjects with ferromagnetic materials in the body, such as dental braces, spinal rods, aneurysm clips, pacemakers, intraocular metal or cochlear implants.
    18. Drug or alcohol abuse in the past 2 years by subject history and/or investigator assessment.
    19. Conditions which could modify the absorption of the study drug, such as inflammatory bowel diseases, or stomach or intestinal resection.
    20. Inability or unwillingness of the subject or subjects’ parents/caregivers to comply with the study procedures.
    21. Other medical, neurological, psychiatric, or social conditions that in the investigator’s opinion are likely to confound the assessment of safety or efficacy, interfere with study conduct, or unfavorably alter the risk-benefit of subject participation.
    22. Pregnant women as confirmed by a positive blood pregnancy test.
    23. Female patients intending to breast feed a child while taking study drug or have taken study drug within 30 days after administration of the last dose.
    1. Alter bei Ausbruch der Erkrankung >25 Jahre.
    2. Linksventrikuläre Ejektionsfraktion (LVEF) <55 % auf dem Echokardiogramm.
    3. Anamnestisch bekannte Herzinsuffizienz, ventrikuläre Arrhythmie, supraventrikuläre Tachykardie oder Vorliegen einer QTcF-Zeit von >480 ms in 3 aufeinander folgenden EKG-Aufzeichnungen, die im Abstand von mindestens 5 Minuten angefertigt wurden.
    4. Bekannte Unverträglichkeit gegenüber Pioglitazon oder anderen Thiazolidindionen.
    5. Aktuelle Einnahme von Pioglitazon oder anderen Thiazolidindionen oder vorherige Einnahme innerhalb von 6 Monaten vor dem Screening.
    6. Aktuelle oder innerhalb von 2 Monaten vor dem Screening erfolgte Teilnahme an einer anderen interventionellen klinischen Studie.
    7. Notwendige Einnahme/Anwendung nicht erlaubter Begleitmedikamente (siehe Tabelle 4). Hinweis: Die Anwendung von Idebenon, Coenzym Q10, Antioxidantien, Riboflavin, Thiamin, Vitamin C und E ist gestattet, vorausgesetzt, dass die Dosis seit ≥3 Monaten vor dem Screening konstant ist und während der gesamten Studie konstant bleibt.
    8. Vorgeschichte oder aktuelles Vorliegen von Blasenpolypen, Blasenzellen-Hyperplasie oder Blasenkrebs.
    9. Vorgeschichte oder aktuelles Vorliegen einer anderen Krebserkrankung, sofern diese nicht operativ entfernt wurde und seit mindestens 5 Jahren kein Rezidiv nachgewiesen wurde.
    10. Klinisch signifikante Anämie (d. h. Hämoglobin unter 110 g/l).
    11. Glykohämoglobin (HbA1c)-Konzentrationen >6,4 % und Nüchtern-Blutzuckerspiegel <das 0,9-Fache der Untergrenze des Normalbereichs und >das 1,1-Fache der Obergrenze des Normalbereichs.
    12. Wert des NT-proB-Typ natriuretischen Peptids (BNP) >125 pg/ml.
    13. Abnormale Leberenzymwerte für Aspartat-Aminotransferase oder Alanin-Aminotransferase von >2-mal der Obergrenze des Normalbereichs oder Gesamtbilirubin >1,5-mal der Obergrenze des Normalbereichs (sofern nicht aufgrund von Gilbert-Syndrom).
    14. Ein positives Ergebnis der Labortests auf Hepatitis-B-Oberflächenantigen, Hepatitis-C-Antikörper und humanes Immundefizienzvirus-Antikörper beim Screening.
    15.Moderate oder schwerwiegende Leberfunktionsstörung (Stadium B oder C der überarbeiteten Child-Pugh-Klassifizierung; siehe Anhang 6.2) (Pugh, Murray-Lyon et al. 1973).
    16.Chronische Nierenerkrankung (CKD) des Stadiums 3a oder höher (gemäß der CKD-Einteilung der Renal Association mit einer geschätzten glomerulären Filtrationsrate von <60 ml/min/1,73 m2).
    17.Studienteilnehmer mit Kontraindikationen für MRS/MRT-Verfahren, wie das Vorhandensein von ferromagnetischem Material im Körper wie z. B. Zahnspangen, Wirbelsäulen-Stäbe, Aneurysma-Clips, Herzschrittmacher, Metall im Auge oder Cochlea-Implantate.
    18.Drogen- oder Alkoholmissbrauch in den letzten 2 Jahren, bewertet anhand der Vorgeschichte des Studienteilnehmers und/oder durch den Prüfarzt.
    19.Erkrankungen/Umstände, die die Aufnahme des Studienmedikaments verändern könnten, wie entzündliche Darmerkrankungen oder die Resektion des Magens oder Darms.
    20.Unfähig- oder Unwilligkeit des Studienteilnehmers oder des Elternteils/Betreuers des Studienteilnehmers zur Einhaltung der Studienverfahren.
    21.Andere medizinische, neurologische, psychiatrische oder soziale Erkrankungen/Zustände, die nach Meinung des Prüfarztes die Bewertung der Sicherheit oder Wirksamkeit nachteilig beeinflussen, die Durchführung der Studie beeinträchtigen oder das Risiko-Nutzen-Verhältnis der Studienteilnahme nachteilig verändern könnten.
    22.Schwangere, bewertet anhand eines positiven Blut-Hormontests.
    23.Patientinnen, die beabsichtigen, während der Einnahme des Studienmedikaments oder innerhalb von 30 Tagen nach der Verabreichung der letzten Dosis ein Kind zu stillen
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in spinal cord area cervical segment C2-C3 [mm2]
    Veränderung im zervikalen Segment C2-C3 (mm2) des Rückenmarksvon Baseline an
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline, week 24 and week 48
    Baseline, Woche 24 und 48
    E.5.2Secondary end point(s)
    Efficacy endpoints include the change from baseline in:
    •Scale for Assessment and Rating of Ataxia:
    -Change from baseline in total score of the SARA
    •Diffusion tensor imaging fractional anisotropy: mean, radial and axial diffusivity cervical segments C2-C7 [10-3 mm2/s]
    •Magnetic resonance spectroscopy tNAA/mIns ratio in spinal cord segments C4-C5
    •MRI quantitative susceptibility mapping for iron concentration
    •Dentate nuclei volume
    •Fixel-based analyses of the brain including fiber density, fiber cross-section and FDC
    •Cerebellar Composite Functional Scale
    •Fatigue Severity Scale (FSS)
    •Activities of Daily Living subscale of FARS
    •Clinical Global Impression – Severity (CGI-S)
    •Clinical Global Impression – Improvement (CGI-I)
    •Patient Global Impression – Improvement (PGI-I)
    •Clinical; Change in slope from baseline of the SARA compared from pre-treatment to post-treatment
    •Neurophysiological ( Motor evoked potentials with central conduction time and amplitude as an optional assessment)
    - Adiponectin in plasma, and CSF (optional)
    - Fatty acid binding protein 4 in CSF (optional)
    - Gene expression of frataxin, PGC-1α, NRF1, TFAM in peripheral blood mononuclear cells
    - Neurofilament light chain in plasma, and CSF (optional)
    •AEs, SAEs & SUSARs
    •vital signs
    •12-lead ECG
    •clinical laboratory tests (included Pregnancy Screen)
    •Physical examination
    E.5.2.1Timepoint(s) of evaluation of this end point
    - All; Baseline, week 24 and week 48
    - CGI-I; Week 24 and week 48
    - PGI-I; week 24 and week 48
    - Safety: From screening, during the 48 weeks of treatment and 4 weeks after discontinuation
    - Palatability: Baseline, week 4, week 12, week 24 and week 36
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA4
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 18
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F. of subjects for this age range: 18
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 18
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    Subjects under age incapable of giving consent personally
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 36
    F.4.2.2In the whole clinical trial 36
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Expected normal treatment of that condition
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-02-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-04-01
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-09-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands